1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Transition Therapeutics Inc. - Product Pipeline Review - 2013

Transition Therapeutics Inc. - Product Pipeline Review - 2013

  • July 2013
  • -
  • Global Markets Direct
  • -
  • 24 pages

Transition Therapeutics Inc. - Product Pipeline Review - 2013

Summary

Global Markets Direct’s pharmaceuticals report, “Transition Therapeutics Inc. - Product Pipeline Review - 2013” provides data on the Transition Therapeutics Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Transition Therapeutics Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Transition Therapeutics Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Transition Therapeutics Inc. - Brief Transition Therapeutics Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Transition Therapeutics Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Transition Therapeutics Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Transition Therapeutics Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Transition Therapeutics Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Transition Therapeutics Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Transition Therapeutics Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Transition Therapeutics Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Transition Therapeutics Inc. and identify potential opportunities in those areas.

Table Of Contents

Transition Therapeutics Inc. - Product Pipeline Review - 2013
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Transition Therapeutics Inc. Snapshot 4
Transition Therapeutics Inc. Overview 4
Key Information 4
Key Facts 4
Transition Therapeutics Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Transition Therapeutics Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Transition Therapeutics Inc. - Pipeline Products Glance 10
Transition Therapeutics Inc. Clinical Stage Pipeline Products 10
Phase I Products/Combination Treatment Modalities 10
Transition Therapeutics Inc. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Transition Therapeutics Inc. - Drug Profiles 12
TT-301 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
TT-302 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
TT-402 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Transition Therapeutics Inc. - Pipeline Analysis 15
Transition Therapeutics Inc. - Pipeline Products by Therapeutic Class 15
Transition Therapeutics Inc. - Pipeline Products By Target 17
Transition Therapeutics Inc. - Pipeline Products by Route of Administration 18
Transition Therapeutics Inc. - Pipeline Products By Mechanism of Action 19
Transition Therapeutics Inc. - Recent Pipeline Updates 20
Transition Therapeutics Inc. - Dormant Projects 21
Transition Therapeutics Inc. - Locations And Subsidiaries 22
Head Office 22
Other Locations and Subsidiaries 22
Appendix 23
Methodology 23
Coverage 23
Secondary Research 23
Primary Research 23
Expert Panel Validation 23
Contact Us 24
Disclaimer 24

List of Tables

Transition Therapeutics Inc., Key Information 4
Transition Therapeutics Inc., Key Facts 4
Transition Therapeutics Inc. - Pipeline by Indication, 2013 7
Transition Therapeutics Inc. - Pipeline by Stage of Development, 2013 8
Transition Therapeutics Inc. - Monotherapy Products in Pipeline, 2013 9
Transition Therapeutics Inc. - Phase I, 2013 10
Transition Therapeutics Inc. - Preclinical, 2013 11
Transition Therapeutics Inc. - Pipeline By Therapeutic Class, 2013 16
Transition Therapeutics Inc. - Pipeline By Target, 2013 17
Transition Therapeutics Inc. - Pipeline By Route of Administration, 2013 18
Transition Therapeutics Inc. - Pipeline Products By Mechanism of Action, 2013 19
Transition Therapeutics Inc. - Recent Pipeline Updates, 2013 20
Transition Therapeutics Inc. - Dormant Developmental Projects,2013 21
Transition Therapeutics Inc., Subsidiaries 22

List of Figures

Transition Therapeutics Inc. - Pipeline by Indication, 2013 6
Transition Therapeutics Inc. - Pipeline by Stage of Development, 2013 8
Transition Therapeutics Inc. - Monotherapy Products in Pipeline, 2013 9
Transition Therapeutics Inc. - Pipeline By Therapeutic Class, 2013 15
Transition Therapeutics Inc. - Pipeline By Route of Administration, 2013 18
Transition Therapeutics Inc. - Pipeline Products By Mechanism of Action, 2013 19

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2016

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2016’, provides in depth analysis ...

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016’, provides in depth analysis ...

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.